Boston, MA -- AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as “AIDS cocktails.” This number represents just 25% of those in need of treatment in these countries. However, little is known about the long-term costs associated with providing drugs to AIDS patients in developing countries. To study those long-term cost trends, researchers from the Harvard School of Public Health have performed the first detailed analysis of AIDS drug cost trends in Brazil. The results appear in the November 13, 2007 issue of the journal PLOS Medicine.
